YaoGeJu

Public drug landscapesDrug landscape

Levocetirizine dihydrochloride Oral Solution

As of 16 November 2026, for Levocetirizine dihydrochloride Oral Solution, 5 applications are listed as under review at China's CDE; 2 companies have filed new generic applications in 2026; the chemical-drug catalogue lists 0 holders.

Companies, stages and changes, with each record available on this page.

Listed in the US FDA Orange Book as XYZAL ALLERGY 24HR (NDA 209090, CHATTEM INC DBA SANOFI CONSUMER HEALTHCARE).

Track this drug free

Free: up to 3 drugs, Monday digest. Sign in with Google or an email code. No card needed.

Complete CDE snapshot
2026/11/16 06:38
Matching scope
Same generic name; dosage forms and combinations kept separate

US Orange Book listing

The brand names come from the US FDA Orange Book and describe US listing records for this active ingredient. They do not indicate that products under these brand names are approved or sold in China, or that Chinese applicants are affiliated with US holders.

Orange Book source export date: 2026/11/06. Version: 2026-11-06.

Showing 2 of 2 distinct brand names.

A brand with different source forms or statuses can appear on multiple rows and in both groups. Distinct brand names are counted once globally, with a limit of five.

Verified official English dosage form: Oral Solution. Listings are grouped by the source dosage form and route; records without a clear correspondence are listed in the other group. Grouping does not establish product equivalence.

Same dosage form

Brand nameApplicant (source text)Application numberDosage form (source text)Route (source text)Marketing status (source text)Approval date
XYZAL ALLERGY 24HR CHATTEM INC DBA SANOFI CONSUMER HEALTHCARE NDA 209090 · Product no. 001 SOLUTION ORAL HUMAN OTC DRUG 2017/01/31
XYZAL CHATTEM INC DBA SANOFI CONSUMER HEALTHCARE NDA 022157 · Product no. 001 SOLUTION ORAL DISCONTINUED 2008/01/28

Other dosage forms of the same ingredient

Brand nameApplicant (source text)Application numberDosage form (source text)Route (source text)Marketing status (source text)Approval date
XYZAL ALLERGY 24HR CHATTEM INC DBA SANOFI CONSUMER HEALTHCARE NDA 209089 · Product no. 001 TABLET ORAL HUMAN OTC DRUG 2017/01/31
XYZAL CHATTEM INC DBA SANOFI CONSUMER HEALTHCARE NDA 022064 · Product no. 001 TABLET ORAL DISCONTINUED 2007/05/25

Same-form/route listings come first, followed by other forms/routes. Within each group, source prescription/OTC listings precede discontinued listings; unknown statuses are last. Each status bucket is ordered by earliest approval date, ascending: pre-1982 records first, missing dates last; ties by brand name, application number and product number. The first five distinct brands in this order are selected globally. All retained source facts for those brands are shown in their own groups; a brand spanning both groups counts once.

Ingredient cross-list details ↗

Which companies are listed, and at what stages?

Each source is counted separately. Expand a list to inspect companies, identifiers, dates and sources.

Legal reference identifiers are retained verbatim. Company labels use official English entries where available, or a visibly marked fixed romanization. Unverified drug names retain the Chinese source name with a No verified English name marker. Other Chinese free text is not displayed; use the source links or source-name columns in CSV exports.

Chemical-drug catalogue

Loaded records: 0 holders; 0 in the quality-and-efficacy consistency-evaluation category, and 0 in the new chemical-registration-classification generic category. Category counts may overlap.

Marketing authorization holderManufacturerApproval numberApprovedStrength / specificationCatalogue category (source text)View source
No matching records were found in the currently loaded source data; coverage dates are listed below.

Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.

NHSA drug codes

Loaded records: 35 distinct approval numbers and 26 companies.

Company / applicantApproval numberStrength / specificationNHSA classNHSA drug codeView source
Beijing Han Mei Medicines Co., Ltd. romanized国药准字H2018300875ml:37.5mgCategory BXR06AEZ066X001010100041NHSA
Beijing SL Pharmaceutical Co., Ltd.国药准字H2026404875ml:37.5mgCategory BXR06AEZ066X001010100148NHSA
Beijing Bai Ya Joint Drug Research Institute Co., Ltd. romanized国药准字H202230490.05%(150ml:75mg)Category BXR06AEZ066X001010100371NHSA
Chongqing Huapont Pharmaceutical Co., Ltd.国药准字H2006128910ml:5mgCategory BXR06AEZ066X001010101003NHSA
Changzhou Si Yao Pharmaceutical Co., Ltd. romanized国药准字H20244915150ml:75mgCategory BXR06AEZ066X001010101389NHSA
Jiangsu Han Chen Pharma Co., Ltd. romanized国药准字H2018339810ml:5mgCategory BXR06AEZ066X001010101442NHSA
Yangtze River Pharmaceutical Group Co., Ltd国药准字H202235350.05%(150ml:75mg)Category BXR06AEZ066X001010101747NHSA
Sichuan Da Zhong Pharmaceutical Co., Ltd. romanized国药准字H202032220.05%(150ml:75mg)Category BXR06AEZ066X001010102132NHSA
Ya Bao Pharma Sichuan Pharmaceutical Co., Ltd. romanized国药准字H2026541275ml:37.5mgCategory BXR06AEZ066X001010102281NHSA
Henan Tong Yuan Pharmaceutical Co., Ltd. romanized国药准字H2018331910ml∶5mgCategory BXR06AEZ066X001010103008NHSA
Jilin Sheng Hui Nan Chang Long Sheng Hua Pharma Co., Ltd. romanized国药准字H2025378510ml:5mgCategory BXR06AEZ066X001010103421NHSA
Zhejiang He Li Xin Jian Pharma Co., Ltd. romanized国药准字H202239740.05%(150ml:75mg)Category BXR06AEZ066X001010104670NHSA
Xiamen Zi Xu Pharmaceuticals Technology Co., Ltd. romanized国药准字H202131340.05%(150ml:75mg)Category BXR06AEZ066X001010104828NHSA
Hunan Jiudian Pharmaceutical Co., Ltd国药准字H2018308910ml:5mgCategory BXR06AEZ066X001010104942NHSA
Hainan Si Da Pharmaceutical Co., Ltd. romanized国药准字H20255137150ml:75mgCategory BXR06AEZ066X001010105816NHSA
Hua Yi Tai Kang Pharma Co., Ltd. romanized国药准字H201831550.05%(10ml:5mg)Category BXR06AEZ066X001010105819NHSA
Hubei Wei Sen Pharmaceutical Co., Ltd. romanized国药准字H2024495275ml:37.5mgCategory BXR06AEZ066X001010106673NHSA
Fu An Pharma Group Hubei Ren Min Pharmaceutical Co., Ltd. romanized国药准字H202345790.05%(75ml:37.5mg)Category BXR06AEZ066X001010109554NHSA
Bei Da Pharmaceuticals Co., Ltd. romanized国药准字H202441945ml:2.5mgCategory BXR06AEZ066X001010109586NHSA
Chongqing Sheng Kai Pharmaceutical Co., Ltd. romanized国药准字H2025335175ml:37.5mgCategory BXR06AEZ066X001010179299NHSA
Beijing Cheng Ji Pharmaceutical Co., Ltd. romanized国药准字H2018310810ml:5mgCategory BXR06AEZ066X001010182209NHSA
Shandong Zhi Tai Pharmaceuticals Technology Co., Ltd. romanized国药准字H20254368150ml:75mgCategory BXR06AEZ066X001010183094NHSA
Anhui Si Huan Ke Bao Pharmaceutical Co., Ltd. romanized国药准字H202648912.5ml:1.25mgCategory BXR06AEZ066X001010183595NHSA
Hefei Guo Gao Pharma Co., Ltd. romanized国药准字H2026544675ml:37.5mgCategory BXR06AEZ066X001010183883NHSA
Zhejiang Yi Han Pharmaceutical Co., Ltd. romanized国药准字H20254365150ml:75mgCategory BXR06AEZ066X001010184227NHSA
Beijing Han Mei Bio Technology Co., Ltd. romanized国药准字H2025439575ml:37.5mgCategory BXR06AEZ066X001010184761NHSA
Chongqing Huapont Pharmaceutical Co., Ltd.国药准字H2006128910ml:5mgCategory BXR06AEZ066X001010201003NHSA
Henan Tong Yuan Pharmaceutical Co., Ltd. romanized国药准字H2018331910ml∶5mgCategory BXR06AEZ066X001010203008NHSA
Xiamen Zi Xu Pharmaceuticals Technology Co., Ltd. romanized国药准字H202131330.05%(75ml:37.5mg)Category BXR06AEZ066X001010204828NHSA
Hunan Jiudian Pharmaceutical Co., Ltd国药准字H2018308910ml:5mgCategory BXR06AEZ066X001010204942NHSA
Hua Yi Tai Kang Pharma Co., Ltd. romanized国药准字H201831550.05%(10ml:5mg)Category BXR06AEZ066X001010205819NHSA
Bei Da Pharmaceuticals Co., Ltd. romanized国药准字H202441945ml:2.5mgCategory BXR06AEZ066X001010209586NHSA
Beijing Cheng Ji Pharmaceutical Co., Ltd. romanized国药准字H2018310810ml:5mgCategory BXR06AEZ066X001010282209NHSA
Anhui Si Huan Ke Bao Pharmaceutical Co., Ltd. romanized国药准字H202648912.5ml:1.25mgCategory BXR06AEZ066X001010283595NHSA
Henan Tong Yuan Pharmaceutical Co., Ltd. romanized国药准字H2018331910ml∶5mgCategory BXR06AEZ066X001010303008NHSA
Hunan Jiudian Pharmaceutical Co., Ltd国药准字H2018308910ml:5mgCategory BXR06AEZ066X001010304942NHSA
Beijing Cheng Ji Pharmaceutical Co., Ltd. romanized国药准字H2018310810ml:5mgCategory BXR06AEZ066X001010382209NHSA
Anhui Si Huan Ke Bao Pharmaceutical Co., Ltd. romanized国药准字H202648912.5ml:1.25mgCategory BXR06AEZ066X001010383595NHSA
Henan Tong Yuan Pharmaceutical Co., Ltd. romanized国药准字H2018331910ml∶5mgCategory BXR06AEZ066X001010403008NHSA
Hunan Jiudian Pharmaceutical Co., Ltd国药准字H2018308910ml:5mgCategory BXR06AEZ066X001010404942NHSA
Beijing Cheng Ji Pharmaceutical Co., Ltd. romanized国药准字H2018310810ml:5mgCategory BXR06AEZ066X001010482209NHSA
Anhui Si Huan Ke Bao Pharmaceutical Co., Ltd. romanized国药准字H202648912.5ml:1.25mgCategory BXR06AEZ066X001010483595NHSA
Henan Tong Yuan Pharmaceutical Co., Ltd. romanized国药准字H2018331910ml∶5mgCategory BXR06AEZ066X001010503008NHSA
Hunan Jiudian Pharmaceutical Co., Ltd国药准字H2018308910ml:5mgCategory BXR06AEZ066X001010504942NHSA
Henan Tong Yuan Pharmaceutical Co., Ltd. romanized国药准字H2018331910ml∶5mgCategory BXR06AEZ066X001010603008NHSA
Hunan Jiudian Pharmaceutical Co., Ltd国药准字H2018308910ml:5mgCategory BXR06AEZ066X001010604942NHSA
Hunan Jiudian Pharmaceutical Co., Ltd国药准字H2018308910ml:5mgCategory BXR06AEZ066X001010704942NHSA
Hunan Jiudian Pharmaceutical Co., Ltd国药准字H2018308910ml:5mgCategory BXR06AEZ066X001010804942NHSA
Hunan Jiudian Pharmaceutical Co., Ltd国药准字H2018308910ml:5mgCategory BXR06AEZ066X001010904942NHSA
Beijing SL Pharmaceutical Co., Ltd.国药准字H20264049200ml:100mgCategory BXR06AEZ066X001020100148NHSA
Beijing Bai Ya Joint Drug Research Institute Co., Ltd. romanized国药准字H202230490.05%(150ml:75mg)Category BXR06AEZ066X001020100371NHSA
Jiangsu Han Chen Pharma Co., Ltd. romanized国药准字H2018339810ml:5mgCategory BXR06AEZ066X001020101442NHSA
Sichuan Da Zhong Pharmaceutical Co., Ltd. romanized国药准字H202032220.05%(150ml:75mg)Category BXR06AEZ066X001020102132NHSA
Ya Bao Pharma Sichuan Pharmaceutical Co., Ltd. romanized国药准字H20265413150ml:75mgCategory BXR06AEZ066X001020102281NHSA
Zhejiang He Li Xin Jian Pharma Co., Ltd. romanized国药准字H202239740.05%(150ml:75mg)Category BXR06AEZ066X001020104670NHSA
Hunan Jiudian Pharmaceutical Co., Ltd国药准字H2018308910ml:5mgCategory BXR06AEZ066X001020104942NHSA
Hua Yi Tai Kang Pharma Co., Ltd. romanized国药准字H201831560.05%(150ml:75mg)Category BXR06AEZ066X001020105819NHSA
Bei Da Pharmaceuticals Co., Ltd. romanized国药准字H2024419510ml:5mgCategory BXR06AEZ066X001020109586NHSA
Chongqing Sheng Kai Pharmaceutical Co., Ltd. romanized国药准字H20253352150ml:75mgCategory BXR06AEZ066X001020179299NHSA
Shandong Zhi Tai Pharmaceuticals Technology Co., Ltd. romanized国药准字H2025436975ml:37.5mgCategory BXR06AEZ066X001020183094NHSA
Anhui Si Huan Ke Bao Pharmaceutical Co., Ltd. romanized国药准字H2026489310ml:5mgCategory BXR06AEZ066X001020183595NHSA
Jiangsu Han Chen Pharma Co., Ltd. romanized国药准字H2018339810ml:5mgCategory BXR06AEZ066X001020201442NHSA
Bei Da Pharmaceuticals Co., Ltd. romanized国药准字H2024419510ml:5mgCategory BXR06AEZ066X001020209586NHSA
Anhui Si Huan Ke Bao Pharmaceutical Co., Ltd. romanized国药准字H2026489310ml:5mgCategory BXR06AEZ066X001020283595NHSA
Jiangsu Han Chen Pharma Co., Ltd. romanized国药准字H2018339810ml:5mgCategory BXR06AEZ066X001020301442NHSA
Anhui Si Huan Ke Bao Pharmaceutical Co., Ltd. romanized国药准字H2026489310ml:5mgCategory BXR06AEZ066X001020383595NHSA
Jiangsu Han Chen Pharma Co., Ltd. romanized国药准字H2018339810ml:5mgCategory BXR06AEZ066X001020401442NHSA
Anhui Si Huan Ke Bao Pharmaceutical Co., Ltd. romanized国药准字H2026489310ml:5mgCategory BXR06AEZ066X001020483595NHSA
Jiangsu Han Chen Pharma Co., Ltd. romanized国药准字H2018339810ml:5mgCategory BXR06AEZ066X001020501442NHSA
Jiangsu Han Chen Pharma Co., Ltd. romanized国药准字H2018339810ml:5mgCategory BXR06AEZ066X001020601442NHSA
Jiangsu Han Chen Pharma Co., Ltd. romanized国药准字H2018339810ml:5mgCategory BXR06AEZ066X001030101442NHSA
Hunan Jiudian Pharmaceutical Co., Ltd国药准字H2018308910ml:5mgCategory BXR06AEZ066X001030104942NHSA
Hua Yi Tai Kang Pharma Co., Ltd. romanized国药准字H201831550.05%(10ml:5mg)Category BXR06AEZ066X001030105819NHSA
Anhui Si Huan Ke Bao Pharmaceutical Co., Ltd. romanized国药准字H202648925ml:2.5mgCategory BXR06AEZ066X001030183595NHSA
Anhui Si Huan Ke Bao Pharmaceutical Co., Ltd. romanized国药准字H202648925ml:2.5mgCategory BXR06AEZ066X001030283595NHSA
Anhui Si Huan Ke Bao Pharmaceutical Co., Ltd. romanized国药准字H202648925ml:2.5mgCategory BXR06AEZ066X001030383595NHSA
Anhui Si Huan Ke Bao Pharmaceutical Co., Ltd. romanized国药准字H202648925ml:2.5mgCategory BXR06AEZ066X001030483595NHSA
Jiangsu Han Chen Pharma Co., Ltd. romanized国药准字H2018339810ml:5mgCategory BXR06AEZ066X001040101442NHSA
Hua Yi Tai Kang Pharma Co., Ltd. romanized国药准字H201831550.05%(10ml:5mg)Category BXR06AEZ066X001040105819NHSA
Hua Yi Tai Kang Pharma Co., Ltd. romanized国药准字H201831550.05%(10ml:5mg)Category BXR06AEZ066X001040205819NHSA
Hua Yi Tai Kang Pharma Co., Ltd. romanized国药准字H201831550.05%(10ml:5mg)Category BXR06AEZ066X001050105819NHSA
Hua Yi Tai Kang Pharma Co., Ltd. romanized国药准字H201831550.05%(10ml:5mg)Category BXR06AEZ066X001050305819NHSA
Jiangsu Han Chen Pharma Co., Ltd. romanized国药准字H2018339810ml:5mgCategory BXR06AEZ066X001060101442NHSA
Hua Yi Tai Kang Pharma Co., Ltd. romanized国药准字H201831550.05%(10ml:5mg)Category BXR06AEZ066X001060105819NHSA
Jiangsu Han Chen Pharma Co., Ltd. romanized国药准字H2018339810ml:5mgCategory BXR06AEZ066X001060201442NHSA
Jiangsu Han Chen Pharma Co., Ltd. romanized国药准字H2018339810ml:5mgCategory BXR06AEZ066X001070101442NHSA
Jiangsu Han Chen Pharma Co., Ltd. romanized国药准字H2018339810ml:5mgCategory BXR06AEZ066X001080101442NHSA
Jiangsu Han Chen Pharma Co., Ltd. romanized国药准字H2018339810ml:5mgCategory BXR06AEZ066X001090101442NHSA
Jiangsu Han Chen Pharma Co., Ltd. romanized国药准字H2018339810ml:5mgCategory BXR06AEZ066X001100101442NHSA

Approval numbers and companies are deduplicated separately; packaging records remain individually listed. An empty insurance class means it is unstated. NHSA codes supply no approval date and do not establish the outcome of an acceptance number.

Current under-review applications

Loaded records: 5 filings and 3 distinct first applicants.

Generic 5

Current under-review applications
Company / applicantAcceptance numberApplication typeAcceptedStrength / specificationView source
Hainan Wan Wei Pharmaceutical Co., Ltd. romanizedCYHS2600450Generic2026/02/11Not stated by sourceCDE
Chongqing He Ping Pharmaceutical Co., Ltd. romanizedCYHS2504113Generic2025/11/29Not stated by sourceCDE
Chongqing He Ping Pharmaceutical Co., Ltd. romanizedCYHS2504112Generic2025/11/29Not stated by sourceCDE
Guangdong Nan Guo Pharma Co., Ltd. romanizedCYHS2602792Generic2026/11/12Not stated by sourceCDE
Guangdong Nan Guo Pharma Co., Ltd. romanizedCYHS2602791Generic2026/11/12Not stated by sourceCDE
New generic filings in 2026

Loaded records: 3 filings and 2 distinct first applicants.

New generic filings in 2026
Company / applicantAcceptance numberApplication typeAcceptedStrength / specificationView source
Hainan Wan Wei Pharmaceutical Co., Ltd. romanizedCYHS2600450Generic2026/02/11Not stated by sourceCDE
Guangdong Nan Guo Pharma Co., Ltd. romanizedCYHS2602792Generic2026/11/12Not stated by sourceCDE
Guangdong Nan Guo Pharma Co., Ltd. romanizedCYHS2602791Generic2026/11/12Not stated by sourceCDE
API registrations

Non-component matches: 12 companies with A status and 2 I-status records. Component matches are listed separately and excluded from these counts.

NameCompany / applicantRegistration numberStatusName matchSource update dateView source
盐酸左西替利嗪 · No verified English nameQi Dong Dong Yue Pharma Co., Ltd. romanizedY20260000499IExact ingredient2026/08/18CDE
盐酸左西替利嗪 · No verified English nameGlochem Industries Private LimitedY20240001166AExact ingredient2026/10/29CDE
盐酸左西替利嗪 · No verified English nameHubei Mei Lin Pharma Co., Ltd. romanizedY20200001504AExact ingredient2026/01/29CDE
盐酸左西替利嗪 · No verified English nameChongqing Hua Bang Sheng Kai Pharmaceutical Co., Ltd. romanizedY20190009441AExact ingredient—CDE
盐酸左西替利嗪 · No verified English nameGranules India LimitedY20190009207AExact ingredient2024/11/29CDE
盐酸左西替利嗪 · No verified English nameZhejiang Yong Ning Pharma Co., Ltd. romanizedY20190007284AExact ingredient2023/05/25CDE
盐酸左西替利嗪 · No verified English nameFu An Pharma Group Ningbo Tian Heng Pharmaceutical Co., Ltd. romanizedY20190006460AExact ingredient2025/09/02CDE
盐酸左西替利嗪 · No verified English nameJiangsu Heng Rui Pharmaceuticals Co., Ltd. romanizedY20190006270AExact ingredient2025/10/16CDE
盐酸左西替利嗪 · No verified English nameSuzhou Dong Rui Pharmaceutical Co., Ltd. romanizedY20190005049AExact ingredient2025/06/28CDE
盐酸左西替利嗪 · No verified English nameHunan Jiu Dian Hong Yang Pharmaceutical Co., Ltd. romanizedY20190004640AExact ingredient2025/07/28CDE
盐酸左西替利嗪 · No verified English nameZhejiang Hai Li Sheng Pharmaceutical Co., Ltd. romanizedY20190003254AExact ingredient—CDE
盐酸左西替利嗪 · No verified English nameShanghai Qing Song Pharmaceutical Co., Ltd. romanizedY20190001278AExact ingredient—CDE
盐酸左西替利嗪 · No verified English nameChongqing Sheng Kai Pharmaceutical Co., Ltd. romanizedY20170002219AExact ingredient2025/04/17CDE
盐酸左西替利嗪 · No verified English nameGlochem Industries LimitedY20170001135IExact ingredient—CDE

A/I are source statuses. Matching uses exact ingredients, salt-normalized names and maintained combination components, without fuzzy matching. A-status companies are deduplicated by the first registered company. Components are excluded from headline counts; the register does not identify the associated formulation.

What changed recently?

Last 90 days, ordered by fact date. Marketing approvals, trial registrations, supplements, notices and review changes are labelled separately.

Trial registration does not mean an application will follow.

This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.

NHSA edition maintained to 2026-10-23; latest successful catalogue check: 2026/11/16 06:35. NHSA records lack approval dates; only an earlier edition or observation establishes precedence.

  1. 2026/11/12Accepted

    Guangdong Nan Guo Pharma Co., Ltd. romanized

    CYHS2602792

    Fact date: 2026/11/12 · Site observation date: 2026/11/13

    View source ↗
  2. 2026/11/12Accepted

    Guangdong Nan Guo Pharma Co., Ltd. romanized

    CYHS2602791

    Fact date: 2026/11/12 · Site observation date: 2026/11/13

    View source ↗
  3. 2026/10/23No longer listed under review

    Yun Peng Pharmaceuticals Group Co., Ltd. romanized; Hua Yi Tai Kang Pharma Co., Ltd. romanized

    CYHB2601792

    Fact date: 2026/10/23 · Site observation date: 2026/10/23

    Accepted: 2026/09/22

    not on the CDE under-review list in this snapshot; NMPA published approval-document delivery for this acceptance number on 2026/10/23 (approval no.: —; approval date: 2026/10/21); this is a supplemental application, not counted as a new marketing approval · NMPA source · row 26

    NMPA · Table row 26 ↗ View source ↗
  4. 2026/10/23No longer listed under review

    Yun Peng Pharmaceuticals Group Co., Ltd. romanized; Hua Yi Tai Kang Pharma Co., Ltd. romanized

    CYHB2601791

    Fact date: 2026/10/23 · Site observation date: 2026/10/23

    Accepted: 2026/09/22

    not on the CDE under-review list in this snapshot; NMPA published approval-document delivery for this acceptance number on 2026/10/23 (approval no.: —; approval date: 2026/10/21); this is a supplemental application, not counted as a new marketing approval · NMPA source · row 25

    NMPA · Table row 25 ↗ View source ↗
  5. 2026/10/21Supplement delivery

    Yun Peng Pharmaceuticals Group Co., Ltd. romanized

    CYHB2601792

    Fact date: 2026/10/21 · Publication date: 2026/10/23 · Site observation date: 2026/11/03

    Supplemental application; excluded from new marketing approvals.

    View source · Table row 26 ↗
  6. 2026/10/21Supplement delivery

    Yun Peng Pharmaceuticals Group Co., Ltd. romanized

    CYHB2601791

    Fact date: 2026/10/21 · Publication date: 2026/10/23 · Site observation date: 2026/11/03

    Supplemental application; excluded from new marketing approvals.

    View source · Table row 25 ↗
  7. 2026/09/22Accepted

    Yun Peng Pharmaceuticals Group Co., Ltd. romanized; Hua Yi Tai Kang Pharma Co., Ltd. romanized

    CYHB2601792

    Fact date: 2026/09/22 · Site observation date: 2026/10/22

    View source ↗
  8. 2026/09/22Accepted

    Yun Peng Pharmaceuticals Group Co., Ltd. romanized; Hua Yi Tai Kang Pharma Co., Ltd. romanized

    CYHB2601791

    Fact date: 2026/09/22 · Site observation date: 2026/10/22

    View source ↗

How current is each source?

CDE acceptances and review
Last successful update: 2026/11/16 06:38
Chemical-drug catalogue
Last successful update: 2026/11/16 06:35

Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.

Full API register
Last successful update: 2026/11/16 06:37
NHSA drug codes
Last successful update: 2026/11/05 06:45

The fully loaded edition was maintained to 2026-10-23. Publication lags maintenance: the verified 2026-10-16 edition was published on 10-28, a 12-day gap. This is not a fixed lag for every edition.

NMPA drug delivery notices
Last successful update: 2026/11/15 18:30

First index-page publication dates: 2026-10-29 to 2026-11-13; 0 pages pending. Covers loaded notices only, not a complete historical approval database.

Drug Clinical Trial Registry and Information Disclosure Platform
Last successful update: 2026/11/16 08:10 · Current coverage may be incomplete

Daily collection reads new registrations. Backfill covers registration numbers from 2025 onward (CTR2025/CTR2026), not first-publication years. States are dated observations; revisions are not tracked.

This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.

Public-product searches scanned: 11/30; discovered pending details: 9. Record counts in unscanned portions remain unknown.

Filings are counted by acceptance number and filing companies by first applicant. Strengths may have separate applications. Drug names are normalized only for width and whitespace; distinct generic names, dosage forms and combinations remain separate. Unstated strengths are marked. Company counts from different sources must not be added together.

Fact dates are approval dates, acceptance dates, trial first-publication dates or complete-snapshot observation dates, as applicable. Publication and site-observation dates are separate. Historical backfills are not current-period new events. Exit records cover currently inactive applications with an identifiable complete snapshot, not a full review history.

Free follow

Follow changes to Levocetirizine dihydrochloride Oral Solution

Up to 3 drugs per email address, in one weekly digest. Starts after email confirmation; unsubscribe at any time.

Confirmation links expire in 7 days. No digest is sent before confirmation; existing follows are not duplicated.

Sign in to choose products

The China drug-review weekly, by email every Monday

No account needed.

Covers all drugs in the loaded CDE records, not only this one: weekly acceptance counts, top-10 lists and definitions. View the latest report

A text version of this report, weekly, in the language you subscribe in. You will receive one confirmation email first; sending starts only after you click its link. Every issue carries an unsubscribe link.